Abcellera Biologics INC 10-Q quarterly reports

AbCellera Biologics Inc. announced its Q2 2026 financial results, showing a significant decline in total revenue and an increased net loss, while also highlighting progress in its clinical programs and new strategic partnerships.

AbCellera Biologics Inc. reported its first quarter 2026 financial results, highlighting increased revenue and progress in its internal drug candidate pipeline, particularly with ABCL635.

AbCellera Biologics reported increased revenue but a wider net loss in Q3 2025, while advancing two antibody therapies into Phase 1 clinical trials and a third into IND/CTA-enabling studies.

AbCellera Biologics reports reduced operating losses and significant clinical pipeline advancements, initiating Phase 1 trials for two antibody therapies while maintaining a strong liquidity position.

AbCellera Biologics' Q1 2025 revenue decreased due to a shift towards internal programs, while R&D expenses increased as the company advances its pipeline.

AbCellera Biologics Inc. reported a net loss of $51.1 million for the third quarter of 2024, with revenue decreasing slightly and operating expenses increasing significantly due to impairment charges.

AbCellera Biologics Inc. reported a decrease in revenue for the second quarter of 2024, alongside increased operating expenses primarily driven by research and development and a significant impairment charge.

AbCellera Biologics Inc. reported a decrease in revenue for the first quarter of 2024, while continuing to invest in research and development and internal programs.